Bluejay Diagnostics Inc (BJDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) has a cash flow conversion efficiency ratio of -0.380x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.59 Million) by net assets ($4.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BJDX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Bluejay Diagnostics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bluejay Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluejay Diagnostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QUHUO LTD SP.ADR/10 CL.A
F:9J40
|
N/A |
|
Eagle Eye Solutions Group plc
LSE:EYE
|
0.125x |
|
France Tourisme Immobilier SA
PA:MLFTI
|
N/A |
|
Fonix Mobile plc
LSE:FNX
|
0.339x |
|
Propell Holdings Ltd
AU:PHL
|
-0.056x |
|
ZAZZ Energy of Sweden AB
ST:ZAZZ-B
|
-0.063x |
|
Cluey Ltd
AU:CLU
|
-0.395x |
|
Dialight plc
LSE:DIA
|
0.032x |
Annual Cash Flow Conversion Efficiency for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Bluejay Diagnostics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Bluejay Diagnostics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.98 Million | $-6.05 Million | -1.013x | +25.77% |
| 2024-12-31 | $5.73 Million | $-7.82 Million | -1.365x | +52.48% |
| 2023-12-31 | $2.89 Million | $-8.31 Million | -2.872x | -328.15% |
| 2022-12-31 | $11.54 Million | $-7.74 Million | -0.671x | -213.08% |
| 2021-12-31 | $20.38 Million | $-4.37 Million | -0.214x | -277.15% |
| 2020-12-31 | $-4.21 Million | $-508.71K | 0.121x | -79.02% |
| 2019-12-31 | $-2.93 Million | $-1.69 Million | 0.576x | -- |
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more